Roivant Sciences Insider Sold Shares Worth $7,262,000
Eric Venker, President of Roivant Sciences and CEO of Immunovant, sold 200,000 shares of Roivant common stock in a transaction reported via SEC filing.
Stocks · News reference
Wolfe Research Downgrades Roivant Sciences to Peer Perform
Wolfe Research analyst Andy Chen downgrades Roivant Sciences (NASDAQ:ROIV) from Outperform to Peer Perform.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Roivant Social Ventures Announces Support for No Patient Left Behind
Roivant Social Ventures (RSV) has pledged a six-figure legacy gift to the non-profit organization No Patient Left Behind to advance drug affordability and patient access.
Roivant and Priovant Announce Positive Phase 3 Results for Brepocitinib in Non-Infectious Uveitis
Roivant Sciences and its subsidiary Priovant Therapeutics reported that the Phase 3 CLARITY program for brepocitinib met primary and key secondary endpoints in patients with non-infectious uveitis.
Roivant Sciences Schedules Second Quarter Fiscal 2026 Financial Results Announcement
Roivant Sciences announced it will release its financial results for the second fiscal quarter ended September 30, 2026, on November 9, 2026.
Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
Immunovant announced it will report financial results for the second fiscal quarter ended September 30, 2026 on November 9, 2026, with a conference call hosted by majority stockholder Roivant Sciences. The company is a clinical-stage immunology firm developing anti-FcRn targeted therapies for autoimmune diseases, with ongoing clinical studies in Graves' disease, myasthenia gravis, and CIDP.
Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)
Roivant and Priovant announced positive Phase 3 results for brepocitinib in treating non-infectious uveitis. The drug met primary and secondary endpoints in both CLARITY-1 and CLARITY-2 trials, with 62% of patients achieving steroid-free quiescence at Week 48 compared to 20% on placebo. The companies plan to file a supplemental New Drug Application in the first half of 2027.